Royalty Pharma Q4 Portfolio Receipts $736M (-31% YoY); FY23 $3,049M (+9%); FY24 guide $2.6-2.7B

Royalty Pharma plc

2023-FY EPS reported $2.53 revenue$2,354,554,000

Portfolio Receipts Q4 $736M (down 31% YoY due to prior-year accelerated Biohaven payments); FY23 $3,049M (+9%).
FY24 guidance: Portfolio Receipts $2.6B-$2.7B, implying royalty receipts growth of 5-9% YoY.
Announced new transactions up to $4.0B in 2023; capital deployed $2.2B in 2023.
Repurchased ~10M shares for $305M in 2023 under $1B buyback program.
Positive clinical updates: aficamten Ph3 success, BMS to acquire Karuna, Novartis to acquire MorphoSys.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Royalty Pharma plc updated its the fourth quarter and full year of 2023 guidance (initiated).

Period: the fourth quarter and full year of 2023
Guidance: initiated
Result: reported results

Exact text from the filing

On February 15, 2024, Royalty Pharma plc issued a press release announcing its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Royalty Pharma plc filing history →

Source: SEC EDGAR

accession 0001802768-24-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.